Skip to main content

Market Overview

FibroGen Upgraded By Mizuho On Continued R&D Progress

Share:
FibroGen Upgraded By Mizuho On Continued R&D Progress

A combination of slightly better-than-expected first-quarter earnings and potential regulatory approval on the horizon have solidified one analysts faith in FibroGen Inc (NASDAQ: FGEN) moving towards the end of the year.

The Analyst

Mizuho’s Difei Yang upgraded shares of FibroGen from Neutral to Buy with a $61 price target.

The Thesis

The company recently reported Q1 earnings. Earnings came in at a loss of 50 cents per share, roughly in line with the consensus estimate, while sales of $31.925 million beat the $27.15 million estimate.

More notably, FibroGen has continued to make progress on its research and development pipelines. In particular, the company’s Roxadustat stood out the Yang. Top-line Phase III data is expected in Q4 this year, and the drug has received priority review from the China FDA, with potential approval arriving by the year’s end.

“We believe the company is likely to gain the first approval in new generation anemia drugs,” Yang said in a note.

The analyst is also looking forward to an update on Pamrevlumab by mid-year 2018, and expects significant upside if it can reproduce its Phase II results in the planned Phase III trial.

Price Action

Shares of FibroGen closed up 2.8 percent at $51.10 on Tuesday.

Related Links:

Benzinga's Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway

The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More

Latest Ratings for FGEN

DateFirmActionFromTo
Apr 2021MizuhoDowngradesBuyNeutral
Apr 2021SVB LeerinkMaintainsOutperform
Apr 2021HC Wainwright & Co.DowngradesBuyNeutral

View More Analyst Ratings for FGEN
View the Latest Analyst Ratings

 

Related Articles (FGEN)

View Comments and Join the Discussion!

Posted-In: Difei Yang mizuho PamrevlumabAnalyst Color Biotech Upgrades Analyst Ratings General Best of Benzinga

Latest Ratings

StockFirmActionPT
ZLABSVB LeerinkMaintains192.0
NVCRNorthland Capital MarketsMaintains250.0
DTEWells FargoMaintains148.0
DUKWells FargoMaintains104.0
CINFRBC CapitalMaintains110.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com